NicOx initiates proof-of-principle clinical study for NCX 6560
First-in-man study for an innovative investigational drug, representing a global therapeutic approach for reduction of cardiovascular risk
20-Mar-2009 -
NicOx S.A. announced the initiation of clinical development for NCX 6560, a novel, nitric oxide-donating compound which could become an improved investigational drug for serious cardiovascular diseases. The first-in-man study will enroll both healthy male volunteers and those with abnormally ...
atherosclerosis
cardiovascular diseases
cholesterol
+5